Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Sanofi inks a Korean alliance to develop a pneumococcal vaccine

The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project.

Circassia begins trading in London following successful IPO

The first two days of trading passed uneventfully, with Circassia's stock fluctuating around the 310 pence ($5.20) per share price it commanded in the IPO to close on Wednesday at 309 pence.

Failure of sexual health clinics to offer HPV vaccine leaves high-risk groups vulnerable

Concerns about cost and promiscuity have led to many countries struggling to increase uptake of human papillomavirus vaccines. England fits into this category, but survey data suggests it has a more fundamental problem: High-risk groups are less likely to be offered the vaccine.

Survey: 1 in 5 Americans think doctors know vaccines cause autism

Andrew Wakefield was struck off the U.K. medical register and The Lancet retracted his paper that linked the MMR vaccine to autism, but the latest survey data suggests one in 5 Americans believe doctors know vaccines cause autism.

Amgen posts positive PhIII data as judgment day for cancer vaccine bet nears

In 2011, Amgen splashed out an initial $425 million to buy BioVex and its cancer vaccine in what analysts described as a "high risk, high reward" deal. A little more than three years later Amgen is close to finding out if the bet has paid off, and the latest data is encouraging.

Novartis to submit Bexsero to FDA in Q2

The use of Bexsero to quell meningitis B outbreaks at two U.S. universities has given Novartis safety data from 14,000 people, but also convinced the Swiss drugmaker it cannot keep shipping the vaccine under investigational use. Novartis has now outlined its plan to make Bexsero more widely available, starting with a submission to FDA in the second quarter.

Analysts offer mixed reactions to Pfizer's Prevnar 13 data close-up

Last month Pfizer presented positive headline results from its massive Prevnar 13 trial, but the release was light on the details that could shape whether the data leads to an expanded recommendation. Now Pfizer has published a closer look at the data, and not everyone likes what they see.

U.K. mulls adopting a 2-dose model for HPV vaccination

If the U.K. adopts the two-shot model, it may use the cash it saves to vaccinate boys against HPV.

ImmusanT waits on early clinical data for its celiac disease vaccine

Over the past 20 years researchers have learned celiac disease is more common than previously thought and is linked strongly to genetic factors. This new knowledge led to the development of two theories--a vaccine for celiac disease can be created, and it could become a big seller.

Study: Vaccinating diabetics against flu cuts risk of death by 28%

Influenza can overwhelm the immune system of people with diabetes and lead to fluctuations in blood sugar levels. Now a study has calculated that reducing the likelihood of these complications by vaccinating against flu is associated with a 28% drop in the risk of death.